Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Key Inclusion Criteria:

Locally advanced unresectable or metastatic GC or GEJ carcinoma and have histologically confirmed adenocarcinoma
No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer. NOTE: Participants may have received prior neoadjuvant or adjuvant therapy as long as it was completed and have no recurrence or disease progression for at least 6 months.
ECOG PS ≤ 1 within 7 days prior to randomization
Adequate organ function as indicated by the following laboratory values ≤ days prior to randomization

Key Exclusion Criteria:

Has squamous cell or undifferentiated or other histological type GC
Active leptomeningeal disease or uncontrolled brain metastasis
Diagnosed with gastric or GEJ adenocarcinoma with positive HER2
Prior therapy with an anti-PD-1, anti-immunotherapy-drugs-are-boosting-survival/" >PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.